Haemonetics Company Profile (NYSE:HAE)

Consensus Ratings for Haemonetics (NYSE:HAE)(?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.

Dividend History for Haemonetics (NYSE:HAE)No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Haemonetics (NYSE:HAE)

Transaction Date

Insider Name

Title

Buy/Sell

Number of Shares

Average Share Price

Total Transaction

Actions

7/20/2015

Christopher J Lindop

CFO

Sell

4,902

$39.09

$191,619.18

7/15/2015

Brian Concannon

CEO

Sell

6,569

$39.59

$260,066.71

7/6/2015

Peter M Allen

Insider

Sell

30,494

$40.19

$1,225,553.86

7/2/2015

Jonathan White

Insider

Sell

2,385

$41.14

$98,118.90

6/22/2015

Christopher J Lindop

CFO

Sell

4,902

$42.51

$208,384.02

6/15/2015

Brian Concannon

CEO

Sell

6,569

$42.51

$279,248.19

6/10/2015

Susan M Hanlon

VP

Sell

6,000

$43.00

$258,000.00

6/1/2015

Brian Concannon

CEO

Sell

4,765

$41.39

$197,223.35

5/20/2015

Christopher J Lindop

CFO

Sell

4,902

$41.65

$204,168.30

5/1/2015

Brian Concannon

CEO

Sell

4,765

$40.74

$194,126.10

4/20/2015

Christopher J Lindop

CFO

Sell

4,902

$41.55

$203,678.10

4/1/2015

Brian Concannon

CEO

Sell

4,765

$44.51

$212,090.15

3/27/2015

Susan M Hanlon

VP

Sell

7,000

$43.46

$304,220.00

3/20/2015

Christopher J Lindop

CFO

Sell

4,902

$44.26

$216,962.52

3/10/2015

Susan Bartlett Foote

Director

Sell

11,328

$43.84

$496,619.52

3/5/2015

Ronald G Gelbman

Director

Sell

7,707

$44.76

$344,965.32

3/4/2015

Ronald Merriman

Director

Sell

14,258

$43.80

$624,500.40

3/2/2015

Brian Concannon

CEO

Sell

4,765

$44.41

$211,613.65

2/18/2015

Pedro P Granadillo

Director

Sell

11,328

$43.45

$492,201.60

2/2/2015

Brian Concannon

CEO

Sell

4,765

$39.15

$186,549.75

1/2/2015

Brian Concannon

CEO

Sell

4,765

$37.20

$177,258.00

12/1/2014

Brian Concannon

CEO

Sell

4,765

$36.72

$174,970.80

11/3/2014

Brian Concannon

CEO

Sell

4,765

$35.86

$170,872.90

10/13/2014

Peter M Allen

Insider

Sell

36,426

$35.22

$1,282,923.72

8/12/2014

Ronald Merriman

Director

Sell

13,602

$35.76

$486,407.52

8/1/2014

Brian Concannon

CEO

Sell

4,380

$35.27

$154,482.60

7/7/2014

Pedro P Granadillo

Director

Sell

5,837

$35.97

$209,956.89

6/12/2014

Ronald G Gelbman

Director

Sell

9,184

$34.00

$312,256.00

6/6/2014

Pedro P Granadillo

Director

Sell

5,837

$34.69

$202,485.53

5/12/2014

Susan Bartlett Foote

Director

Sell

9,184

$33.16

$304,541.44

5/7/2014

Pedro Granadillo

Director

Sell

5,837

$31.14

$181,764.18

5/1/2014

Brian Concannon

CEO

Sell

4,600

$30.01

$138,046.00

4/28/2014

Peter Allen

Insider

Sell

30,000

$30.70

$921,000.00

4/7/2014

Pedro Granadillo

Director

Sell

5,837

$31.98

$186,667.26

4/1/2014

Brian Concannon

CEO

Sell

4,600

$32.71

$150,466.00

3/6/2014

Ronald Gelbman

Director

Sell

12,000

$36.17

$434,040.00

3/3/2014

Brian Concannon

CEO

Sell

4,600

$36.36

$167,256.00

2/18/2014

Susan Hanlon

VP

Sell

3,690

$39.00

$143,910.00

2/7/2014

Jonathan White

Insider

Sell

1,880

$38.66

$72,680.80

2/3/2014

Brian Concannon

CEO

Sell

7,600

$37.63

$285,988.00

1/27/2014

Susan Hanlon

VP

Sell

3,206

$38.37

$123,014.22

1/10/2014

Susan Hanlon

VP

Sell

4,000

$41.80

$167,200.00

1/2/2014

Brian Concannon

CEO

Sell

7,600

$41.58

$316,008.00

12/16/2013

Susan Hanlon

VP

Sell

4,000

$43.50

$174,000.00

12/9/2013

Susan Hanlon

VP

Sell

3,138

$43.07

$135,153.66

12/2/2013

Brian Concannon

CEO

Sell

7,600

$42.31

$321,556.00

11/12/2013

Michael Kelly

Insider

Sell

61,400

$39.70

$2,437,580.00

11/1/2013

Brian Concannon

CEO

Sell

7,600

$39.96

$303,696.00

10/14/2013

Michael Kelly

Insider

Sell

1,400

$40.41

$56,574.00

9/13/2013

Michael Kelly

Insider

Sell

1,400

$40.36

$56,504.00

9/3/2013

Brian Concannon

CEO

Sell

13,000

$39.87

$518,310.00

8/1/2013

Brian Concannon

CEO

Sell

13,000

$42.24

$549,120.00

7/12/2013

Michael P Kelly

Insider

Sell

1,400

$44.10

$61,740.00

7/1/2013

Brian Concannon

CEO

Sell

13,000

$41.87

$544,310.00

6/18/2013

Christopher J Lindop

CFO

Sell

68,628

$42.50

$2,916,690.00

6/14/2013

Michael P Kelly

Insider

Sell

1,400

$42.17

$59,038.00

6/3/2013

Brian Concannon

CEO

Sell

13,000

$41.15

$534,950.00

5/21/2013

Christopher J Lindop

CFO

Sell

42,882

$42.00

$1,801,044.00

5/14/2013

Michael P Kelly

Insider

Sell

1,400

$39.66

$55,524.00

5/1/2013

Brian Concannon

CEO

Sell

13,000

$38.66

$502,580.00

12/3/2012

Brian Concannon

CEO

Sell

13,000

$40.75

$529,750.00

11/12/2012

Pedro P Granadillo

Director

Sell

16,000

$80.40

$1,286,400.00

9/4/2012

Brian Concannon

CEO

Sell

6,500

$73.68

$478,920.00

9/4/2012

Christopher J Lindop

CFO

Sell

61,783

$74.34

$4,592,948.22

(Data available from 1/1/2013 forward)

About Haemonetics

Haemonetics Corporation is a healthcare company engaged in providing blood management solutions to its customers. The Company's portfolio of integrated devices, information management and consulting services offers blood management solutions for each facet of the blood supply chain, helping improve clinical outcomes and reduce costs for blood and plasma collectors, hospitals, and patients around the world.The Company serves three markets: manufacturers of plasma derived pharmaceuticals, blood collectors and hospitals. Plasma includes plasma collection devices and consumables. Blood Center includes blood collection and processing devices and consumables. Hospital includes surgical blood salvage and blood demand diagnostic devices and consumables. Software Solutions includes information technology platforms and consulting services provided to all three markets. On April 30, 2013, the Company acquired of certain assets of Hemerus LLC.